This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Investigations

Authoring team

The investigations of choice in cholecystitis are:

  • FBC – usually shows leucocytosis
  • liver function test – to detect any obstructive jaundice (1)
  • inflammatory markers - looking for an elevated white cell count, and raised C-reactive protein (2)
  • abdominal x-ray:
    • can reveal radio-opaque stones in minority of cases
    • may show air in the biliary tree
    • can rule out intra-abdominal free air – seen in diverticulitis or perforated peptic ulcer (3)
  • ultrasound:
    • recommended for any suspected acute cholecystitis
    • first-choice imaging method for the morphological diagnosis of acute cholecystitis (3)
    • diagnosis of acute cholecystitis is made radiologically when the following are present at the same time (4):
      • thickening of the gallbladder wall (5 mm or greater)
      • pericholecystic fluid
      • ultrasonographic Murphy’s sign
        • pain which occurs when the probe is pushed against the gallbladder
        • superior to ordinary Murphy’s sign
    • other findings may include: gallbladder enlargement, gallbladder stones, debris echo and gas imaging
  • magnetic resonance cholangiopancreatography (MRCP):
    • can obtain images of the whole of the biliary tree and adjacent structures
    • small stones can be detected
    • request MRCP if ultrasound has not detected common bile duct stones but the bile duct is dilated and/or liver function test results are abnormal (5)
  • CT scan:
    • finding may include: gallbladder distention (41%), gallbladder wall thickening (59%), pericholecystic fat density (52%), pericholecystic fluid collection (31%) (6)
    • recommended for diagnosing gangrenous cholecystitis and emphysematous cholecystitis (6)
  • radio-isotopic scanning – HIDA scanning:
    • has a sensitivity of 80–90% for acute cholecystitis
    • normally outlines the gall bladder and duct system
    • if gallbladder is obstructed, cannot take up contrast, hence, not shown
    • ‘rim sign’ (a blush of increased pericholecystic radioactivity) is present in about 30% of patients with acute cholecystitis and in about 60% with acute gangrenous cholecystitis (6)
    • usually reserved for patients in whom diagnosis is unclear after ultrasonography (6)

References:

  1. Dawson J. Acute cholecystitis. GPonline 2009
  2. Yokoe M, Hata J, Takada T, et al. Tokyo guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):41-54.
  3. Association of Upper Gastrointestinal Surgeons. Pathway for the management of acute gallstone diseases. September 2015 [internet publication].
  4. Bortoff GA, Chen MY, Ott DJ, et al. Gallbladder stones: imaging and intervention. Radiographics. 2000 May-Jun;20(3):751-66.
  5. National Institute for Health and Care Excellence. Gallstone disease: diagnosis and management. October 2014 [internet publication].
  6. Yokoe M, et al.Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):41-54. doi: 10.1002/jhbp.515. Epub 2018 Jan 9. PMID: 29032636.
  7. Strasberg SM. Clinical practice. Acute calculous cholecystitis. N Engl J Med. 2008;358(26):2804-11.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.